SCHEMBL7126685

SCHEMBL7126685

COc1ccc(NS(=O)(=O)c2ccc(Cl)cc2)c(C(=O)Nc2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC20A2 Q08357 1/20 0.83
SLC20A1 Q8WUM9 1/20 0.83
RXFP1 Q9HBX9 3/20 0.54
IDH2 P48735 2/20 0.53
CNR2 P34972 1/20 0.52
AVPR2 P30518 3/20 0.52
GPR27 Q9NS67 3/20 0.52
SLC10A2 Q12908 1/20 0.52
SLC10A1 Q14973 1/20 0.52
SLC10A6 Q3KNW5 1/20 0.52
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.52
POLB P06746 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 1/20 0.52
SLC2A1 P11166 1/20 0.51
P2RX1 P51575 1/20 0.51
P2RX4 Q99571 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128814 0.91 SLC20A2 (1.00) SLC20A2SLC20A1RXFP1IDH2AVPR2
SCHEMBL5115424 0.89 SLC20A2 (0.66) SLC20A2SLC20A1RXFP1IDH2CNR2
SCHEMBL5117189 0.86 SLC10A6 (0.72) SLC20A2SLC20A1RXFP1CNR2AVPR2
SCHEMBL5119995 0.85 RXFP1 (0.70) SLC20A2SLC20A1RXFP1AVPR2GPR27
SCHEMBL5120085 0.85 SLC20A2 (0.63) SLC20A2SLC20A1AVPR2GPR27SLC10A2
SCHEMBL7631719 0.83 SLC20A2 (0.86) SLC20A2SLC20A1RXFP1AVPR2GPR27
SCHEMBL10249599 0.80 GPR27 (0.66) SLC20A2SLC20A1AVPR2GPR27SLC10A2
SCHEMBL5110940 0.80 SLC10A6 (0.68) SLC20A2SLC20A1AVPR2GPR27SLC10A2
SCHEMBL5125728 0.80 SLC10A6 (0.61) SLC20A2SLC20A1AVPR2GPR27SLC10A2
SCHEMBL6862230 0.80 SLC20A2 (0.66) SLC20A2SLC20A1AVPR2GPR27SLC10A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US claimed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP claimed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO claimed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO claimed
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US disclosed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP disclosed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO disclosed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216449-A1 Phosphate transport inhibitors SLC34A2, SLC34A1, SLC34A3 SLC20A2 4/4885SLC20A1 5/4885RXFP1 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.